Eurofins Scientific announces 58% revenue growth for 2006
Brussels/ Nantes, February 14, 2007
In the 2006 fiscal year Eurofins Scientific Group generated consolidated revenues of € 368.0 m (€ 233.1m 2005) which have now more than doubled since 2004 (€175.5m). This represents growth of 58% from 2005 and is higher than previous guidance given due to a strong final quarter and recent acquisitions. Organic growth for the year was about 10%.
The breakdown in revenues by region is as follows:
|
 |
At present it is expected that EBIT for the year 2006 will reach the target of € 36m which was set in January of last year.
The full annual results will be published on 28th February 2007. Management presentations will be held on that day in both Paris and Frankfurt. Further comments on performance will only be given then.
For further information please visit www.eurofins.com or contact:
Investor Relations |
|
|---|---|
|
Dr. Stefan Eckhoff (International Investor Relations) Tél : +32-2-766 16 20 E-mail : ir@eurofins.com |
Hugues Vaussy (Investor Relations France) Tél: +33-(0)2-51 83 21 00 E-mail: irFrance@eurofins.com |
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 5,000 staff in more than 70 laboratories across 24 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext on the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.